Ocumension Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was HK$3,577.8 Mil.
During the past 12 months, Ocumension Therapeutics's average Total Assets Growth Rate was 24.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 53.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 268.20% per year.
During the past 6 years, Ocumension Therapeutics's highest 3-Year average Total Assets Growth Rate was 752.50%. The lowest was 53.60%. And the median was 248.70%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Ocumension Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (HKSE:01477) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Ocumension Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Ocumension Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Ocumension Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocumension Therapeutics (HKSE:01477) Business Description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01477 has been successfully added to your 